Bladder Ca
67 programs · 66 companies
Programs
67
Companies
66
Trials
74
MOAs
43
GLP-1/GIPKRASG12DiCDK4/6iTYK2iWEE1iEZH2iIL-23iFGFRiPRMT5iIL-17i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Phase 2/3 | FLT3 | ||
| Ivotuximab | NDA/BLA | GIP-R | ||
| NBI-3153 | Approved | Aβ | ||
| ITC-879 | Approved | FcRn | ||
| Talatuximab | Preclinical | CD3 | ||
| ASN-7038 | Phase 3 | VEGF | ||
| Adagraderotide | Phase 2 | EGFR | ||
| Motatinib | Preclinical | MDM2 | ||
| Capirelsin | Phase 2 | FLT3 | ||
| ABC-4950 | Phase 2 | JAK1 | ||
| Pexazanubrutinib | Preclinical | TROP-2 | ||
| CHI-IIT-962 | Preclinical | KIF18A | ||
| EOR-IIT-902 | NDA/BLA | GPRC5D | ||
| HOV-IIT-284 | Phase 1 | CD19 | ||
| IMM-7144 | Approved | PI3Kα | ||
| Miritinib | Approved | KIF18A | ||
| Olpasacituzumab | Phase 3 | EGFR | ||
| Terarelsin | Phase 3 | KRASG12C | ||
| Capilucimab | Phase 3 | TYK2 | ||
| Zorilemzoparlimab | Approved | CDK2 | ||
| Datoglumide | Phase 2 | Tau | ||
| IMA-217 | NDA/BLA | HER2 | ||
| Capitapinarof | Phase 3 | EZH2 | ||
| Capilemzoparlimab | Phase 2 | VEGF | ||
| CYD-4746 | Phase 1 | PCSK9 | ||
| AVE-316 | Phase 3 | SHP2 | ||
| Semaglumide | Approved | SGLT2 | ||
| DRR-2203 | Phase 2/3 | CDK2 | ||
| Gelizasiran | Phase 3 | RET | ||
| Fixabrutinib | Preclinical | C5 | ||
| CNT-6977 | Preclinical | SOS1 | ||
| CLE-2655 | Phase 2 | GPRC5D | ||
| CAR-3300 | Approved | FXIa | ||
| PBL-1430 | Phase 1/2 | CD19 | ||
| OCU-3469 | Phase 1 | LAG-3 | ||
| FRE-IIT-864 | Phase 2 | TYK2 | ||
| Fixafutibatinib | Phase 1 | Cl18.2 | ||
| GEN-IIT-346 | Approved | GLP-1R | ||
| PSI-4605 | Preclinical | BCL-2 | ||
| 456-9934 | Phase 1/2 | WRN | ||
| Elralucimab | Phase 1 | PCSK9 | ||
| Tezesacituzumab | Phase 1/2 | KRASG12C | ||
| TOR-3576 | NDA/BLA | EZH2 | ||
| Ivolemzoparlimab | Approved | DLL3 | ||
| REC-7914 | NDA/BLA | PLK4 | ||
| RCE-2070 | Phase 1/2 | FGFR | ||
| NVC-9528 | Phase 2 | FGFR | ||
| NEO-1781 | NDA/BLA | DLL3 | ||
| POL-2929 | Phase 2/3 | GPRC5D | ||
| Tixanesiran | Phase 2 | PRMT5 | ||
| Zoriinavolisib | Phase 2/3 | WRN | ||
| Mirimavacamten | Phase 1/2 | PI3Kα | ||
| Cevirelsin | Phase 2 | TYK2 | ||
| Zenoinavolisib | NDA/BLA | PLK4 | ||
| CHA-IIT-658 | Phase 1/2 | APOC3 | ||
| CHA-IIT-211 | Phase 1 | GPRC5D | ||
| RIK-IIT-299 | Preclinical | SHP2 | ||
| PRI-IIT-117 | Preclinical | MALT1 | ||
| WES-IIT-660 | Phase 1 | SHP2 | ||
| Polasertib | Phase 1/2 | Aβ | ||
| WST-9696 | Phase 3 | PCSK9 | ||
| Talatuximab | Phase 2 | AuroraA | ||
| ADA-2164 | Approved | FcRn | ||
| ACG-4705 | NDA/BLA | BET | ||
| Talalemzoparlimab | Phase 2/3 | IL-23 | ||
| Capifotisoran | Approved | TIGIT | ||
| ZHE-9252 | Phase 3 | FLT3 |
Trials (74)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07067690 | NBI-3153 | Approved | Terminated |
| NCT04262575 | NBI-3153 | Approved | Recruiting |
| NCT06213469 | NBI-3153 | Approved | Completed |
| NCT07932078 | ITC-879 | Approved | Terminated |
| NCT05622652 | ITC-879 | Approved | Recruiting |
| NCT05236630 | Talatuximab | Preclinical | Terminated |
| NCT07598392 | ASN-7038 | Phase 3 | Completed |
| NCT05488817 | ASN-7038 | Phase 3 | Not yet recr... |
| NCT06912077 | Adagraderotide | Phase 2 | Terminated |
| NCT07937433 | Capirelsin | Phase 2 | Active |
| NCT06514262 | ABC-4950 | Phase 2 | Completed |
| NCT03478200 | ABC-4950 | Phase 2 | Recruiting |
| NCT07977542 | Pexazanubrutinib | Preclinical | Active |
| NCT03554100 | CHI-IIT-962 | Preclinical | Active |
| NCT04780482 | EOR-IIT-902 | NDA/BLA | Completed |
| NCT03818864 | HOV-IIT-284 | Phase 1 | Recruiting |
| NCT07304793 | IMM-7144 | Approved | Not yet recr... |
| NCT06879663 | Miritinib | Approved | Completed |
| NCT05025198 | Olpasacituzumab | Phase 3 | Recruiting |
| NCT06054065 | Olpasacituzumab | Phase 3 | Terminated |